Read by QxMD icon Read

Lupus disease activity

Mónica Vázquez-Del Mercado, Felipe de J Perez-Vazquez, Eduardo Gomez-Bañuelos, Efrain Chavarria-Avila, Arcelia Llamas-García, Karla I Arrona-Rios, Gustavo Ignacio Diaz-Rubio, Sergio Durán-Barragán, Rosa E Navarro-Hernández, Bethel P Jordán-Estrada, Natalia Prado-Bachega, Miguel A A Gonzalez-Beltran, Carlos Ramos-Becerra, Fernando Grover-Paez, David Cardona-Müller, Ernesto G Cardona-Muñoz
It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic illness. In the last decades, there has been a growing development of different methodologies with the purpose of early detection of CVD. OBJECTIVE: The aim of this study is to correlate the usefulness of subclinical parameters of vascular aging and QRISK 3-2017 score for early detection of CVD in SLE. METHODS: Clinical assessment including systemic lupus erythematosus disease activity index (SLEDAI) and systemic lupus international collaborating clinics / american college of rheumatology damage index (SLICC/ACR DI), laboratory measurements, carotid ultrasound examination, carotid intima media thickness (cIMT) measurement, carotid distention and diameter analysis, arterial stiffness measurement measured by tonometry and QRISK 3-2017 were done...
2018: PloS One
María Del Carmen Zamora-Medina, Andrea Hinojosa-Azaola, Carlos A Nuñez-Alvarez, Angel Gabriel Vargas-Ruiz, Juanita Romero-Diaz
OBJECTIVE: To validate the association of thrombotic events with positive lupus anticoagulant (LA) and co-presence of anti-RNP/Sm, as well as the diagnostic accuracy of this combination of antibodies for thrombosis. METHODS: Case-control study of patients with systemic lupus erythematosus (SLE) who presented thrombosis after SLE diagnosis and controls with SLE without thrombosis. Comorbidities, traditional risk factors, clinical variables, and treatment were evaluated...
December 4, 2018: Clinical Rheumatology
Michelle P Ashton, Anne Eugster, Sevina Dietz, Doreen Loebel, Annett Lindner, Denise Kuehn, Anna E Taranko, Babett Heschel, Anita Gavrisan, Anette-Gabriele Ziegler, Martin Aringer, Ezio Bonifacio
OBJECTIVE: To identify single cell transcriptional signatures of dendritic cells (DCs) associated with autoimmunity and determine if those signatures correlate with the clinical heterogeneity of autoimmune disease. METHODS: Blood-derived DCs were single-cell sorted from patients with rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes and were analyzed using single-cell gene expression assays immediately after isolation or after in vitro stimulation...
December 4, 2018: Arthritis & Rheumatology
B C Tiseo, E Bonfá, E F Borba, G A Munhoz, Gja Wood, M Srougi, C A Silva, M Cocuzza
OBJECTIVE: To evaluate sperm DNA fragmentation analysis in non-azoospermic male systemic lupus erythematosus (SLE) patients. METHODS: Twenty-eight consecutive male SLE patients (American College of Rheumatology criteria) and 34 healthy controls were evaluated for demographic/exposures data, urological evaluation, hormone profile and sperm analysis (including sperm DNA fragmentation). Clinical features, disease activity/damage scores and treatment were also evaluated...
December 3, 2018: Lupus
A Sarkissian, V Sivaraman, S Bout-Tabaku, S P Ardoin, M Moore-Clingenpeel, V Mruk, H Steigelman, K Morris, S A Bowden
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) have altered bone metabolism and are at risk of osteoporosis. The aim of this study was to examine bone turnover markers in relation to vitamin D, disease activity, and clinical risk factors in patients with established SLE. METHODS: Clinical registry and biorepository data of 42 SLE patients were assessed. Serum samples were analyzed for osteocalcin as a marker of bone formation, C-terminal telopeptide of type 1 collagen (CTX) as a marker for bone resorption, and 25-hydroxy vitamin D...
December 3, 2018: Lupus
Alexis Mathian, Suzanne Mouries-Martin, Karim Dorgham, Hervé Devilliers, Laura Barnabei, Elyès Ben Salah, Fleur Cohen-Aubart, Laura Garrido Castillo, Julien Haroche, Miguel Hie, Marc Pineton de Chambrun, Makoto Miyara, Delphine Sterlin, Micheline Pha, Du Lê Thi Huong, Frédéric Rieux-Laucat, Flore Rozenberg, Guy Gorochov, Zahir Amoura
OBJECTIVES: No simple or standardized assay is available to quantify interferon-α (IFNα) in routine clinical practice. Single-molecule-array (Simoa) digital enzyme-linked immunosorbent assay (ELISA) technology enables direct IFNα quantification at fg/mL concentrations. This study was undertaken to assess IFNα digital ELISA diagnostic performances to monitor systemic lupus erythematosus (SLE) activity. METHODS: IFNα concentrations in serum samples from 150 consecutive SLE patients in a cross-sectional study were determined with digital ELISA and a functional biological activity assay (bioassay)...
December 3, 2018: Arthritis & Rheumatology
(no author information available yet)
No abstract text is available yet for this article.
December 2018: Journal of Rheumatology
John M Gansner, Nancy Berliner
Catastrophic antiphospholipid antibody syndrome (CAPS) and macrophage activation syndrome (MAS) are both life-threatening hematologic disorders that infrequently afflict patients with rheumatologic disease. CAPS is characterized by fulminant multiorgan damage related to small vessel thrombosis in the setting of persistent antiphospholipid antibodies. It can occur in patients with rheumatologic diseases such as systemic lupus erythematosus but can also affect patients who do not have rheumatologic disease. By contrast, the term MAS is applied when patients with rheumatologic disease develop hemophagocytic lymphohistiocytosis (HLH); therefore, patients with MAS have an underlying rheumatologic disease by definition...
November 30, 2018: Hematology—the Education Program of the American Society of Hematology
Xiao-Yun Jia, Qing-Qing Zhu, Yuan-Yuan Wang, Yang Lu, Zhi-Jun Li, Bai-Qing Li, Jie Tang, Hong-Tao Wang, Chuan-Wang Song, Chang-Hao Xie, Lin-Jie Chen
BACKGROUND: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1)-targeted therapies have enhanced T-cell response and demonstrated efficacy in the treatment of multiple cancers. However, the role and clinical significance of PD-L1 expression on CD19+ B-cells and their subsets, with particular reference to systemic lupus erythematosus (SLE), have not yet been studied in detail. OBJECTIVE: The present study aimed to investigate PD-L1 expression on CD19+ B-cells and their subsets, in addition to exploring its possible role in Tfh-cell activation and B-cell differentiation in SLE...
November 28, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
E A A Christou, A Banos, D Kosmara, G K Bertsias, D T Boumpas
Systemic lupus erythematosus (SLE) is characterized by aberrant production of auto-antibodies and a sexual dimorphism both in the phenotypic expression and frequency of the disease between males and females. The striking female predominance was initially attributed primarily to sex hormones. However, recent data challenge this simplistic view and point more towards genetic and epigenetic factors accounting for this difference. More specifically, several SLE-associated single-nucleotide polymorphisms (SNPs) have been found to play an important role in the gender predilection in SLE...
December 1, 2018: Lupus
G C Jing, Y Chen, L Wang, D Xu, W J Zheng, M T Li, X F Zeng, F C Zhang
A 45-year-old woman was admitted to the Department of Rheumatology and Immunology, Peking Union Medical College Hospital, due to weakness of the upper limbs, fever, and blurred vision. She was clinically diagnosed as systemic lupus erythematosus overlapped primary biliary cirrhosis, with renal, retinal, hematological and musculoskeletal involvement, combined with severe pulmonary infection and respiratory failure. Treated with glucocorticoids, ursodeoxycholic acid, antibiotics and respiratory support, the patient got better...
December 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
Pooja Poudel, Thein Swe, Sheetal Rayancha
Macrophage activation syndrome (MAS) itself is a rare, potentially life-threatening complication of a rheumatic disease, mostly seen in juvenile idiopathic arthritis. It infrequently occurs in systemic lupus erythematosus (SLE), and it is extremely rare to be the first presentation of SLE. In a study of 511 patients with SLE, 7 cases (1.4%) of MAS were identified. In all the cases, MAS was simultaneous to the presentation of SLE in this article, we report a case of a patient with MAS who presented with fever, rash, and high ferritin level up to 16911 ng/mL...
January 2018: Journal of Investigative Medicine High Impact Case Reports
Simone Caielli, Diogo Troggian Veiga, Preetha Balasubramanian, Shruti Athale, Bojana Domic, Elise Murat, Romain Banchereau, Zhaohui Xu, Manjari Chandra, Cheng-Han Chung, Lynnette Walters, Jeanine Baisch, Tracey Wright, Marilynn Punaro, Lorien Nassi, Katie Stewart, Julie Fuller, Duygu Ucar, Hideki Ueno, Joseph Zhou, Jacques Banchereau, Virginia Pascual
Understanding the mechanisms underlying autoantibody development will accelerate therapeutic target identification in autoimmune diseases such as systemic lupus erythematosus (SLE)1 . Follicular helper T cells (TFH cells) have long been implicated in SLE pathogenesis. Yet a fraction of autoantibodies in individuals with SLE are unmutated, supporting that autoreactive B cells also differentiate outside germinal centers2 . Here, we describe a CXCR5- CXCR3+ programmed death 1 (PD1)hi CD4+ helper T cell population distinct from TFH cells and expanded in both SLE blood and the tubulointerstitial areas of individuals with proliferative lupus nephritis...
November 26, 2018: Nature Medicine
Stefan Vordenbäumen, Ralph Brinks, Annika Hoyer, Rebecca Fischer-Betz, Georg Pongratz, Torsten Lowin, Hans-Dieter Zucht, Petra Budde, Ellen Bleck, Peter Schulz-Knappe, Matthias Schneider
OBJECTIVE: to appraise the role of epitope spreading in established human systemic lupus erythematosus (SLE). METHODS: IgG-autoantibody reactivity to 398 distinct recombinant proteins was measured in 69 SLE patients over 6 years and compared to 45 controls. Changes in mean fluorescence intensity (MFI), number of autoantibodies to distinct antigens, and reactivity to distinct clones of selected established antigenic targets U1-RNP, Sm, and ribosomal P representing epitope fine mapping were assessed...
November 26, 2018: Arthritis & Rheumatology
Edoardo Sciatti, Ilaria Cavazzana, Enrico Vizzardi, Ivano Bonadei, Micaela Fredi, Mara Taraborelli, Romina Ferizi, Marco Metra, Angela Tincani, Franco Franceschini
BACKGROUND: Accelerated atherosclerosis, responsible for premature cardiovascular disease, has been estimated to develop or progress in 10% of systemic lupus erythematosus (SLE) patients each year and to be 6-fold more frequent in SLE compared with the general population. The mechanisms underlying accelerated atherosclerosis in SLE are complex and involve classical and "non-classical" cardiovascular risk factors. Subclinical and disseminated atherosclerosis is associated with endothelial dysfunction and arterial stiffness...
November 25, 2018: Current Rheumatology Reviews
Michelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, Hang Phuong Pham, Fabien Pitoiset, Karim El Soufi, Claire RIbet, Claude Bernard, Selim Aractingi, Beatrice Banneville, Laurent Beaugerie, Francis Berenbaum, Julien Champey, Olivier Chazouilleres, Christophe Corpechot, Bruno Fautrel, Arsène Mekinian, Elodie Regnier, David Saadoun, Joe-Elie Salem, Jérémie Sellam, Philippe Seksik, Anne Daguenel-Nguyen, Valérie Doppler, Jéremie Mariau, Eric Vicaut, David Klatzmann
OBJECTIVE: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. AIM: We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases...
November 24, 2018: Annals of the Rheumatic Diseases
Leilei Wen, Lu Liu, Ke Xue, Yong Cui
Systemic lupus erythematosus (SLE) is a chronic heterogeneous autoimmune disease characterized by loss of tolerance to self-antigens, complement activation, dysregulated type 1 IFN responses, and immune-mediated tissue damage. The clinical features of SLE are pleomorphic, affecting virtually any organ system, such as skin, joints, central nervous system, or kidneys. Currently, the etiology and pathogenesis of SLE are not fully understood. Generally, it is considered that genetic factors, immune abnormalities, sex hormones, and environmental factors are associated with SLE, and mainly caused by genetic and environmental interactions, typical for a complex disease with multiple susceptibility genes...
December 2018: Journal of Investigative Dermatology. Symposium Proceedings
Eun Wha Choi, Ji Woo Song, Nina Ha, Young Il Choi, Sungjoo Kim
Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease with an unknown etiology. Recently, it has been elucidated that dysregulated histone deacetylase (HDAC) activity is related to the pathogenesis of inflammatory and autoimmune diseases. Broad-spectrum HDAC inhibitors are effective for the treatment of allergy, cancer, and autoimmune diseases, but they have several adverse side effects. Thus, the purpose of this study was to evaluate the effects of a novel HDAC 6-specific inhibitor, CKD-506, in a murine SLE model...
November 23, 2018: Scientific Reports
Sophia L Ryan, Shamik Bhattacharyya
Connective tissue disorders are now understood to include autoimmune and genetic diseases affecting organs, blood vessels, and surrounding fascia. Many of these diseases predominantly affect women in childbearing years and are associated with neurologic complications. Pregnancy can affect disease activity (such as flares of systemic lupus erythematosus), and the diseases can affect pregnancy outcome (such as increased risk of preterm labor). We review the neurologic complications and changes with pregnancy for systemic lupus erythematosus, Sjögren syndrome, idiopathic inflammatory myopathy, and Marfan syndrome...
February 2019: Neurologic Clinics
Diana C Salazar-Camarena, Pablo Ortíz-Lazareno, Miguel Marín-Rosales, Alvaro Cruz, Francisco Muñoz-Valle, Raziel Tapia-Llanos, Gerardo Orozco-Barocio, René Machado-Contreras, Claudia A Palafox-Sánchez
BACKGROUND: Systemic lupus erythematosus (SLE) is the prototype of systemic autoimmune disease, characterized by loss of immune tolerance against self-antigens where autoantibody production is the hallmark of disease. B-cell-activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are cytokines that promote autoreactive cell survival, immunoglobulin-class switching and autoantibody responses in human and mouse SLE models. BAFF and APRIL exert their functions through interactions with their receptors BAFF-R and TACI that are differentially expressed in B lymphocyte subsets, monocytes, dendritic cells and T lymphocytes...
November 19, 2018: Cytokine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"